Aim: This paper presents the results of a study regarding fungemia made in three tertiary hospitals from Iaşi between 2001 and 2005.

Material and method: The study has included a total number of 32 patients hospitalized in surgery or intensive care departments and whose blood cultures exhibited fungemia due to yeasts. The clinical strains have been identified on the basis of morphological and biochemical features, while the antifungal susceptibility testing has been performed using ATB fungus 2 strips and voriconazole disks. The significance of minimal inhibitory concentrations has been interpreted according to CLSI standards.

Results: The frequency of species implied in fungemia etiology has been the following: Candida albicans 31.25%, C. parapsilosis 12.50%, C. tropicalis 9.38%, C. pelliculosa 9.38%, C. krusei 6.25%, C. sake 6.25%, C. dubliniensis 3.12%, C. norvegiensis 3.12%, C. norvegica 3.12%, C. kefyr
3.12%, C. intermedia 3.12%, C. valida 3.12%, Rhodotorula glutinis 3.12%, and Trichosporon asahii 3.12%. The resistance rate to main antifungals has varied between 0.00% in case of amphotericin B and voriconazole, and 12.50% for itraconazole. The mortality in patients diagnosed with yeast fungemia has been of 38%.

Disscusion: It can be noted a relatively low frequency of C. albicans strains and the emergence of fungemia due to non-albicans species accordingly to worldwide trends. The resistance rate to antifungals is still low, the fluconazole being the first intention drug recommended in fight against bloodstream yeast infections. The liposomal amphotericin B and voriconazole could be used as a successfully alternative therapy in azoles resistant infections.